-
Medytox Shifts Strategy for China Market Entry with Next-Generation Botulinum Toxin
•
Korea-based biopharmaceutical company Medytox has reportedly revamped its strategy for entering the Chinese market, according to Koreabiomed.com. After withdrawing a drug registration filing for its Meditoxin/Neuronox (Botulinum toxin type A; BTX) with the National Medical Products Administration (NMPA) in 2018, Medytox is now setting its sights on introducing Newlux, a…
-
MicroPort MedBot’s Toumai Robot Gains NMPA Approval for Endoscopic Surgery
•
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252), a leading medical robotics company, has announced that it has received market approval from the National Medical Products Administration (NMPA) for its Toumai endoscopic surgery robot. This approval allows the robot to be used across multiple departments for a variety of surgical…
-
Danaher Corporation Reports Q3 2023 Earnings with 10.5% Global Revenue Decline
•
US-based science and tech services giant Danaher Corporation (NYSE: DHR) has reported its Q3 2023 earnings, with global revenues experiencing a 10.5% year-on-year (YOY) decline to USD 6.9 billion, resulting in net earnings of USD 1.1 billion. CEO Rainer M. Blair highlighted that revenues surpassed forecasts, driven by increased respiratory…
-
AstraZeneca Licenses Nanoform’s Starmap AI Platform to Enhance Drug Development
•
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has obtained a license from Finnish drug design expert Nanoform Finland (HEL: NANOFH) for Starmap, an innovative AI-enabled platform. This platform facilitates confidential in silico testing of molecule candidates prior to chemical synthesis, aiming to reduce clinical attrition throughout the drug development pipeline.…
-
EC Approves AstraZeneca and Daiichi Sankyo’s Enhertu for Advanced HER2+ NSCLC
•
The European Commission (EC) has granted registration approval for the HER2-directed antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) to AstraZeneca (AZ; NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568). This approval is for the treatment of advanced HER2-positive non-small cell lung cancer (NSCLC) in adults who require systemic therapy following chemotherapy. The…
-
Dizal’s Sunvozertinib Shows Promising Efficacy in Advanced NSCLC at ESMO 2023
•
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented compelling efficacy and safety data for its next-generation epidermal growth factor receptor (EGFR) inhibitor, sunvozertinib, at the European Society for Medical Oncology (ESMO) Congress 2023. The drug is being evaluated for first-line treatment in advanced non-small cell lung cancer (NSCLC) with EGFR…
-
AbbVie Partners with Lupus Therapeutics to Advance Rinvoq in SLE Treatment
•
AbbVie (NYSE: ABBV) announced this week a strategic collaboration with US-based Lupus Therapeutics aimed at accelerating the late-stage development of the JAK inhibitor Rinvoq (upadacitinib) for the treatment of systemic lupus erythematosus (SLE). This partnership marks a significant step in expanding the therapeutic applications of Rinvoq, which is already approved…
-
BMS’s BMS-986278 Receives FDA Breakthrough Therapy Designation for Pulmonary Fibrosis
•
Bristol-Myers Squibb (BMS; NYSE: BMY) announced this week that it has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for BMS-986278, its potential first-in-class lysophosphatidic acid receptor 1 (LPA1) antagonist. This oral treatment for progressive pulmonary fibrosis (PPF) is now set for expedited development and review,…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis Novo Nordisk NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
